Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy

Abstract

Purpose Glioma is the most prevalent malignant form of brain tumors, with a dismal prognosis. Currently, cancer immunotherapy has emerged as a revolutionary treatment for patients with advanced highly aggressive therapy-resistant tumors. However, there is no effective biomarker to reflect the response to immunotherapy in glioma patient so far. So we aim to assess the clinical predictive value of FCER1G in patients with glioma. Methods The expression level and correlation between clinical prognosis and FER1G levels were analyzed with the data from CGGA, TCGA, and GEO database. Univariate and multivariate cox regression model was built to predict the prognosis of glioma patients with multiple factors. Then the correlation between FCER1G with immune cell infiltration and activation was analyzed. At last, we predict the immunotherapeutic response in both high and low FCER1G expression subgroups. Results FCER1G was significantly higher in glioma with greater malignancy and predicted poor prognosis. In multivariate analysis, the hazard ratio of FCER1G expression (Low versus High) was 0.66 and 95 % CI is 0.54 to 0.79 (P < 0.001), whereas age (HR = 1.26, 95 % CI 1.04–1.52), grade (HR = 2.75, 95 % CI 2.06–3.68), tumor recurrence (HR = 2.17, 95 % CI 1.81–2.62), IDH mutant (HR = 2.46, 95 % CI 1.97–3.01) and chemotherapeutic status (HR = 1.4, 95 % CI 1.20–1.80) are also included. Furthermore, we illustrated that gene FCER1G stratified glioma cases into high and low FCER1G expression subgroups that demonstrated with distinct clinical outcomes and T cell activation. At last, we demonstrated that high FCER1G levels presented great immunotherapeutic response in glioma patients. Conclusions This study demonstrated FCER1G as a novel predictor for clinical diagnosis, prognosis, and response to immunotherapy in glioma patient. Assess expression of FCER1G is a promising method to discover patients that may benefit from immunotherapy.

Establishment of a nomogram with EMP3 for predicting clinical outcomes in patients with glioma: A bi‐center study

“… 37 , 38 In our previous study, we revealed that FCER1G is a novel predictor for clinical prognosis and response to immunotherapy in glioma patients, which is of great clinical significance and will contribute to the development of individualized management plans. 39 …”

Immunotherapeutic Approaches for Glioblastoma Treatment

“…FcRγ has been implicated in tumor progression and associated with poorer outcomes when overexpressed. Additionally, in this group’s large cohort of over 1000 patients, it was confirmed that the FCER1G is a novel predictor of patients who respond to immunotherapy effectively [ 178 ].…”

“…Another group identified FCER1G (FcRγ) as a potential biomarker for GBM immunotherapy [ 178 ]. This molecule is involved in allergic reactions and encodes the immunoglobulin γ subunit of fragment crystallizable (Fc) region (FcR) [ 179 ].…”

Identification of FCER1G related to Activated Memory CD4+ T Cells Infiltration by Gene Co-expression Network and Construction of a Risk Prediction Module in Diffuse Large B-Cell Lymphoma

“…Fc Fragment of IgE Receptor Ig ( FCER1G ) mediates allergic inflammatory signaling as a component of the high-affinity immunoglobulin E (IgE) receptor, and it is a critical molecule in developing eczema, clear cell renal cell carcinoma, meningioma and childhood leukemia ( Han et al, 2010 ; Mahachie John et al, 2010 ; Rajaraman et al, 2010 ; Chen et al, 2017 ). Houshi Xu et al demonstrated FCER1G as a novel predictor for clinical diagnosis, prognosis, and response to immunotherapy in glioma patients ( Xu et al, 2021 ). Early studies found that FCER1G transduced activation signals from various immunoreceptors and engaged in many immune responses, playing a tumor-promoting role in many kinds of tumors ( Shah et al, 2017 ; Sweet et al, 2017 ).…”